Truist raised the firm’s price target on Collegium Pharmaceutical to $37 from $31 and keeps a Buy rating on the shares. The company’s financial update solidifies its renegotiation efforts that kick-started in 2022 across Xtampza ER payors, the analyst tells investors in a research note. Collegium has pulled all the right levers throughout 2023 to optimize shareholder value, Truist added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on COLL:
- Collegium Pharmaceutical board authorizes $150M share repurchase program
- Collegium Pharmaceutical sees 2024 product revenue $580M-$595M
- Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 Patent
- Collegium announces appeal courts upholds decision on Purdue ‘961 patent
- Collegium Pharmaceutical announces $25M accelerated share repurchase program
